201 reports of this reaction
1.3% of all GLECAPREVIR AND PIBRENTASVIR reports
#11 most reported adverse reaction
INSOMNIA is the #11 most commonly reported adverse reaction for GLECAPREVIR AND PIBRENTASVIR, manufactured by AbbVie Inc.. There are 201 FDA adverse event reports linking GLECAPREVIR AND PIBRENTASVIR to INSOMNIA. This represents approximately 1.3% of all 15,159 adverse event reports for this drug.
Patients taking GLECAPREVIR AND PIBRENTASVIR who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is a less commonly reported adverse event for GLECAPREVIR AND PIBRENTASVIR, but still significant enough to appear in the safety profile.
In addition to insomnia, the following adverse reactions have been reported for GLECAPREVIR AND PIBRENTASVIR:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 201 FDA reports for GLECAPREVIR AND PIBRENTASVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 1.3% of all adverse event reports for GLECAPREVIR AND PIBRENTASVIR, making it a notable side effect.
If you experience insomnia while taking GLECAPREVIR AND PIBRENTASVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.